Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 9/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169457 | 0.85 | ADA (0.49) | ADATBXAS1LPAR1 | |
| SCHEMBL5671897 | 0.85 | ADA (0.47) | ADATBXAS1PARP10 | |
| SCHEMBL6169467 | 0.84 | ADA (0.48) | ADALPAR1 | |
| SCHEMBL6939027 | 0.83 | ADA (0.40) | ADATBXAS1PARP10 | |
| SCHEMBL6133929 | 0.82 | ADA (0.52) | ADATBXAS1 | |
| SCHEMBL6134007 | 0.81 | ADA (0.41) | ADA | |
| SCHEMBL6171160 | 0.81 | ADA (0.44) | ADATBXAS1LPAR1PTGER1 | |
| SCHEMBL5672381 | 0.81 | ADA (0.41) | ADATBXAS1 | |
| SCHEMBL5672394 | 0.81 | ADA (0.39) | ADARBP4 | |
| SCHEMBL6173997 | 0.80 | ADA (0.42) | ADATBXAS1LPAR1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885TBXAS1 540/4885PARP10 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.